| http://www.w3.org/ns/prov#value | - The formulation of claim 3, wherein said formulation comprises histidine is at a concentration of about 10 mM to about 50 mM and the palivizumab or palivizumab antigen-binding fragment is at a concentration of at least 100 mg/ml, and wherein said formulation further comprises an excipient other than a surfactant.
|
